Skip to main content
NASDAQ:NVAX

Novavax Competitors

$131.69
+10.69 (+8.83 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$118.31
$136.36
50-Day Range
$121.00
$257.67
52-Week Range
$38.05
$331.68
Volume4.23 million shs
Average Volume4.27 million shs
Market Capitalization$9.76 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.01

Competitors

Novavax (NASDAQ:NVAX) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying NVAX stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Novavax, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Novavax (NASDAQ:NVAX) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Analyst Ratings

This is a summary of current ratings for Novavax and Amgen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novavax11402.50
Amgen291402.48

Novavax currently has a consensus price target of $216.3333, indicating a potential upside of 64.27%. Amgen has a consensus price target of $255.6190, indicating a potential upside of 1.69%. Given Novavax's stronger consensus rating and higher probable upside, equities research analysts plainly believe Novavax is more favorable than Amgen.

Risk and Volatility

Novavax has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Insider & Institutional Ownership

49.9% of Novavax shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 3.3% of Novavax shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Novavax and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novavax-133.10%-1,346.17%-45.85%
Amgen29.42%95.55%15.52%

Valuation and Earnings

This table compares Novavax and Amgen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$18.66 million522.91$-132,690,000.00($5.80)-22.71
Amgen$23.36 billion6.18$7.84 billion$14.8216.96

Amgen has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Novavax on 9 of the 14 factors compared between the two stocks.

Novavax (NASDAQ:NVAX) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Insider & Institutional Ownership

49.9% of Novavax shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 3.3% of Novavax shares are owned by insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Novavax has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.

Profitability

This table compares Novavax and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novavax-133.10%-1,346.17%-45.85%
Gilead Sciences5.48%37.77%12.76%

Valuation and Earnings

This table compares Novavax and Gilead Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$18.66 million522.91$-132,690,000.00($5.80)-22.71
Gilead Sciences$22.45 billion3.83$5.39 billion$6.1411.16

Gilead Sciences has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Novavax and Gilead Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novavax11402.50
Gilead Sciences091202.57

Novavax currently has a consensus price target of $216.3333, indicating a potential upside of 64.27%. Gilead Sciences has a consensus price target of $100.5909, indicating a potential upside of 46.78%. Given Novavax's higher probable upside, equities research analysts plainly believe Novavax is more favorable than Gilead Sciences.

Summary

Gilead Sciences beats Novavax on 10 of the 14 factors compared between the two stocks.

Novavax (NASDAQ:NVAX) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Insider and Institutional Ownership

49.9% of Novavax shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 3.3% of Novavax shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Novavax has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares Novavax and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novavax-133.10%-1,346.17%-45.85%
Vertex Pharmaceuticals38.51%28.55%20.68%

Valuation & Earnings

This table compares Novavax and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$18.66 million522.91$-132,690,000.00($5.80)-22.71
Vertex Pharmaceuticals$4.16 billion13.50$1.18 billion$4.2950.60

Vertex Pharmaceuticals has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Novavax and Vertex Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novavax11402.50
Vertex Pharmaceuticals041612.86

Novavax presently has a consensus price target of $216.3333, indicating a potential upside of 64.27%. Vertex Pharmaceuticals has a consensus price target of $293.4737, indicating a potential upside of 35.19%. Given Novavax's higher probable upside, analysts clearly believe Novavax is more favorable than Vertex Pharmaceuticals.

Summary

Vertex Pharmaceuticals beats Novavax on 11 of the 15 factors compared between the two stocks.

Novavax (NASDAQ:NVAX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Insider and Institutional Ownership

49.9% of Novavax shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 3.3% of Novavax shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Novavax has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500.

Profitability

This table compares Novavax and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novavax-133.10%-1,346.17%-45.85%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Valuation & Earnings

This table compares Novavax and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$18.66 million522.91$-132,690,000.00($5.80)-22.71
Regeneron Pharmaceuticals$7.86 billion7.04$2.12 billion$21.4724.06

Regeneron Pharmaceuticals has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Novavax and Regeneron Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novavax11402.50
Regeneron Pharmaceuticals051402.74

Novavax presently has a consensus price target of $216.3333, indicating a potential upside of 64.27%. Regeneron Pharmaceuticals has a consensus price target of $656.3810, indicating a potential upside of 27.05%. Given Novavax's higher probable upside, analysts clearly believe Novavax is more favorable than Regeneron Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats Novavax on 11 of the 14 factors compared between the two stocks.

Novavax (NASDAQ:NVAX) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Insider and Institutional Ownership

49.9% of Novavax shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 3.3% of Novavax shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Novavax has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Profitability

This table compares Novavax and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novavax-133.10%-1,346.17%-45.85%
Biogen35.63%51.00%23.54%

Valuation & Earnings

This table compares Novavax and Biogen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$18.66 million522.91$-132,690,000.00($5.80)-22.71
Biogen$14.38 billion2.93$5.89 billion$33.578.35

Biogen has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Novavax and Biogen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novavax11402.50
Biogen4141202.27

Novavax presently has a consensus price target of $216.3333, indicating a potential upside of 64.27%. Biogen has a consensus price target of $305.5714, indicating a potential upside of 9.05%. Given Novavax's stronger consensus rating and higher probable upside, analysts clearly believe Novavax is more favorable than Biogen.

Summary

Biogen beats Novavax on 9 of the 14 factors compared between the two stocks.

Novavax (NASDAQ:NVAX) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Insider and Institutional Ownership

49.9% of Novavax shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 3.3% of Novavax shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Novavax has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Profitability

This table compares Novavax and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novavax-133.10%-1,346.17%-45.85%
Alexion Pharmaceuticals16.32%23.16%14.76%

Valuation & Earnings

This table compares Novavax and Alexion Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$18.66 million522.91$-132,690,000.00($5.80)-22.71
Alexion Pharmaceuticals$4.99 billion7.68$2.40 billion$9.7417.81

Alexion Pharmaceuticals has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Novavax and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novavax11402.50
Alexion Pharmaceuticals015402.21

Novavax presently has a consensus price target of $216.3333, indicating a potential upside of 64.27%. Alexion Pharmaceuticals has a consensus price target of $159.3158, indicating a potential downside of 8.17%. Given Novavax's stronger consensus rating and higher probable upside, analysts clearly believe Novavax is more favorable than Alexion Pharmaceuticals.

Summary

Alexion Pharmaceuticals beats Novavax on 9 of the 13 factors compared between the two stocks.


Novavax Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$251.38+0.4%$144.43 billion$23.36 billion20.27Insider Selling
Gilead Sciences logo
GILD
Gilead Sciences
2.8$68.53+0.6%$85.95 billion$22.45 billion70.65
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$217.09+1.3%$56.20 billion$4.16 billion27.41
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$516.62+0.1%$55.35 billion$7.86 billion18.88Analyst Report
Biogen logo
BIIB
Biogen
1.5$280.21+0.5%$42.19 billion$14.38 billion9.28
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$173.49+0.1%$38.34 billion$4.99 billion40.54
Seagen logo
SGEN
Seagen
1.5$147.50+1.9%$26.77 billion$916.71 million58.07Insider Selling
Incyte logo
INCY
Incyte
1.6$82.62+0.7%$18.17 billion$2.16 billion-52.62Analyst Report
Exact Sciences logo
EXAS
Exact Sciences
2.0$96.74+3.2%$16.60 billion$876.29 million-43.77Analyst Report
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$135.70+2.0%$15.95 billion$219.75 million-17.33
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$76.93+1.8%$14.06 billion$1.70 billion17.60Insider Selling
Repligen logo
RGEN
Repligen
1.9$171.96+1.3%$9.44 billion$270.24 million209.71Analyst Report
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$94.60+2.8%$8.94 billion$788.10 million101.72Analyst Report
Unusual Options Activity
United Therapeutics logo
UTHR
United Therapeutics
1.7$197.87+2.1%$8.86 billion$1.45 billion18.72Analyst Report
Exelixis logo
EXEL
Exelixis
1.9$25.56+0.4%$8.01 billion$967.78 million53.25Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$43.03+2.9%$6.13 billion$195.99 million268.94Earnings Announcement
Analyst Downgrade
Insider Selling
Analyst Revision
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$38.24+2.3%$5.39 billion$1.12 billion79.67Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$61.46+1.6%$3.73 billion$806.43 million-8.71Analyst Report
Alkermes logo
ALKS
Alkermes
1.2$22.26+0.1%$3.57 billion$1.17 billion-48.39Insider Selling
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$62.00+5.6%$3.32 billion$1.11 billion19.94Analyst Report
Gap Up
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.4$9.49+1.3%$2.52 billion$182.24 million-8.25Earnings Announcement
Analyst Revision
OPKO Health logo
OPK
OPKO Health
1.9$3.70+7.8%$2.48 billion$901.90 million-20.55Insider Buying
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$12.84+6.9%$2.28 billion$48.83 million-16.89
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.5$134.70+2.3%$2.23 billionN/A-12.17
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$129.52+4.4%$2.16 billion$120.28 million-130.83
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.38+6.3%$2.11 billion$638.60 million-10.53
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$11.68+1.7%$1.88 billion$428.41 million16.93
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.85+4.1%$1.56 billion$102.43 million-18.08Analyst Revision
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.75+5.2%$1.35 billion$82.27 million-16.46Earnings Announcement
Analyst Revision
Gap Up
Innoviva logo
INVA
Innoviva
1.1$12.87+0.9%$1.30 billion$261.02 million6.57
Curis logo
CRIS
Curis
1.3$13.57+3.7%$1.24 billion$10 million-16.55Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
Codexis logo
CDXS
Codexis
1.5$18.29+3.8%$1.18 billion$68.46 million-52.26
MannKind logo
MNKD
MannKind
1.4$4.31+6.5%$1.07 billion$63.04 million-20.52Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$27.09+7.7%$1.07 billion$3.57 million-12.15Gap Up
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$18.65+1.3%$1.04 billion$227.19 million51.81Analyst Report
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$7.80+6.0%$893.79 million$35.22 million-5.69Analyst Downgrade
ChemoCentryx logo
CCXI
ChemoCentryx
1.7$10.44+4.5%$728.19 million$36.13 million-15.58Analyst Report
Agenus logo
AGEN
Agenus
1.6$3.23+6.2%$718.48 million$150.05 million-2.96Analyst Upgrade
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.17+4.4%$683.21 million$150,000.00-4.53Analyst Report
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$18.79+2.4%$682.60 millionN/A0.00High Trading Volume
Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.71+2.4%$631.31 million$59.29 million-24.73
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.33+3.0%$625.20 million$322.07 million-4.12Analyst Revision
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$5.87+4.3%$613.80 million$143.01 million-1.12Analyst Report
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$18.15+5.1%$601.89 million$252 million-1.86Analyst Report
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.48+12.1%$541.88 million$109.33 million-2.56Earnings Announcement
News Coverage
Verastem logo
VSTM
Verastem
1.5$2.94+4.8%$505.44 million$17.46 million-2.09Earnings Announcement
Analyst Report
News Coverage
Geron logo
GERN
Geron
1.4$1.43+6.3%$455.55 million$460,000.00-4.09Earnings Announcement
Analyst Upgrade
Analyst Revision
Gap Up
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.86+6.1%$440.85 million$22.27 million-3.85Earnings Announcement
News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$3.68+1.9%$357.90 million$36.63 million-4.33Upcoming Earnings
XOMA logo
XOMA
XOMA
1.5$29.92+2.1%$337.20 million$18.37 million-26.95
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.